New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:31 EDTARGSArgos data shows disease eradication potential, says JMP Securities
JMP Securities believes that immunological data from patients on Argos' AGS-004 indicates that the drug can affect latent reservoirs of HIV virus. The firm views this as a key step in virus eradication, and it thinks the data suggest the drug can be effectively combined with PD-1/PDL-1 inhibitors in HIV and oncology. It reiterates an Outperform rating on the stock.
News For ARGS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2015
08:36 EDTARGSArgos Therapeutics announces formation of Scientific Advisory Board
Argos Therapeutics announced the formation of the company's first Scientific Advisory Board. Jeff Abbey, president and CEO of Argos, stated, "Forming a scientific advisory board is another important step as we continue to build Argos into a fully-integrated, commercial immuno-oncology company. These oncology and immunology experts will provide us with guidance on many clinical and technical aspects of our development programs. Their input is especially welcome as we continue our pivotal phase 3 ADAPT clinical trial of our lead product candidate, AGS-003, for the treatment of metastatic renal cell carcinoma, and as we plan to begin testing AGS-003 in other tumor types."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use